Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
L L Wang(Children's Hospital of Los Angeles), Hiroyuki Shimada(National Center for Geriatrics and Gerontology)
Cited by 152
Related Papers
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
|Nature Medicine|2023|125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
|Clinical Cancer Research|2018|88
Large cell neuroblastoma
|Cancer|2004|50